Implementing an Innovative Lipid Management Technique Using siRNA LDL-C Lowering Therapy: Lessons Learned in an NHS Primary Care Practice With Worked Case Examples
Introduction: The UK Government partnered with industry to tackle cardiovascular disease (CVD) in the first NHS population health agreement. The ambition was to prevent 150 000 strokes, heart attacks and dementia cases over the next 10 years with a new siRNA LDL-C lowering therapy (Inclisiran) deliv...
Main Authors: | Carl Deaney, Meredith Donaldson, Agne Meskauskiene |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-05-01
|
Series: | Journal of Primary Care & Community Health |
Online Access: | https://doi.org/10.1177/21501319231172709 |
Similar Items
-
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
by: Yanzhen Zhang, et al.
Published: (2023-10-01) -
siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
by: Bo Hu, et al.
Published: (2023-06-01) -
Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting
by: Carl N. Deaney, et al.
Published: (2024-03-01) -
Lipid-Based Formulations for siRNA Delivery
by: Foged, C, et al.
Published: (2009) -
Advances in Lipid Nanoparticles for siRNA Delivery
by: Sam Chen, et al.
Published: (2013-09-01)